BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study (Q35630278)

9 August 2017

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study (English)

1 reference

9 August 2017

1 reference

David B Zhen

1

0 references

Nicholas J Roberts

object named as

Nicholas J Roberts

10

0 references

Daniela Seminara

16

object named as

Daniela Seminara

1 reference

9 August 2017

7

Ralph H Hruban

1 reference

9 August 2017

3

Steven Gallinger

1 reference

9 August 2017

2

Kari G Rabe

1 reference

9 August 2017

18

Gloria M Petersen

1 reference

9 August 2017

5

Ann G Schwartz

1 reference

9 August 2017

17

Alison P Klein

1 reference

9 August 2017

6

Michael G Goggins

1 reference

9 August 2017

8

Michele L Cote

1 reference

9 August 2017

Sapna Syngal

4

1 reference

9 August 2017

Robert R McWilliams

9

1 reference

9 August 2017

Lisa A Cannon-Albright

11

1 reference

9 August 2017

Donghui Li

12

1 reference

9 August 2017

Kelsey Moyes

13

1 reference

9 August 2017

Richard J Wenstrup

14

1 reference

9 August 2017

Anne-Renee Hartman

15

1 reference

9 August 2017

language of work or name

English

0 references

publication date

20 November 2014

1 reference

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

7

1 reference

9 August 2017

569-577

1 reference

https://scigraph.springernature.com/pub.10.1038/gim.2014.153

9 August 2017

0 references

cites work

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Identifying people at a high risk of developing pancreatic cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Clinical significance of large rearrangements in BRCA1 and BRCA2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Absence of germline BRCA1 mutations in familial pancreatic cancer patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Pancreatic cancer genetic epidemiology consortium

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Cancer Incidence in BRCA1 mutation carriers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Cancer risks in BRCA2 mutation carriers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Genetic susceptibility to pancreatic cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

BRCA1 and pancreatic cancer: pedigree findings and their causal relationships

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

CDKN2A germline mutations in familial pancreatic cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

15 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439391

Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families

15 November 2018

1 reference

12 December 2020

Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations

1 reference

12 December 2020

Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds

1 reference

12 December 2020

The prevalence of BRCA2 mutations in familial pancreatic cancer

1 reference

12 December 2020

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

1 reference

12 December 2020

Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer

1 reference

12 December 2020

Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics

1 reference

12 December 2020

PALB2 mutations in European familial pancreatic cancer families

1 reference

12 December 2020

Identifiers

DOI

10.1038/GIM.2014.153

1 reference

9 August 2017

1 reference

9 August 2017

1 reference